RAS LifeScience Solutions

Seegene Inc., a leading South Korean company in #PCR #MolecularDiagnostics, has developed new PCR test assays in response to the #PHEIC (Public Health Emergency of International Concern) declared by the #WHO due to the global spread of #Mpox. These research-use-only (#RUO) products include the Novaplex™ MPXV/OPXV Assay (RUO) and the Novaplex™ HSV-1&2/VZV/MPXV Assay (RUO). The #Novaplex assays are designed to detect four viruses simultaneously, delivering highly reliable results with dual internal controls. These innovations are part of #Seegene’s commitment to addressing #GlobalHealth needs and providing tailored assays for specific country requirements. Both assays feature dual internal controls (Endogenous Internal Control and Exogenous Internal Control) within the same tube, ensuring the integrity of the sample and verifying the entire testing process for highly reliable results. #GlobalHealth #Diagnostics #PublicHealth #MultiplexPCR #InfectiousDiseases #HealthcareInnovation #Seegene #Mpox #PHEIC #RUO #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization  For detailed News: https://lnkd.in/dbNuu7Su Follow our page for more industry updates: https://lnkd.in/de5zNWmK

In Season 2, Episode 13 of our Pipeline Analysis, we present Bayer’s second-quarter updates for 2024. 📊 Total Sales: €11.1 billion R&D Expenses: €1.5 billion Free Cash Flow: €1.3 billion Pharmaceutical Division Highlights: Revenue: €4.6 billion R&D Expenses: €0.82 billion Key Revenue Generators: Xarelto, Eylea, Nubeqa, Mirena 🌟 Noteworthy Developments: Aflibercept was submitted for approval in China for neovascular age-related macular degeneration (nAMD) Bayer has seven cell and gene therapy programs at various stages across multiple therapy areas #Bayer #Pharmaceuticals #Innovation #Healthcare #R&D #Biotech #PipelineAnalysis #FutureOfMedicine

🌟 De Novo FDA Approvals in July 2024! 🌟 July 2024 has brought two groundbreaking FDA #Approvals, marking significant advancements in the #Pharmaceutical industry. These new drugs introduce #CuttingEdge #Treatment options and bring renewed hope to patients in need. #FDA #PharmaInnovation #NewDrugs #Healthcare #PatientCare #PharmaNews #Kisunla #Alopecia #Dermatology #Leqselvi #AD #MCI #Neuroscience Eli Lilly and Company SUN PHARMA Sun Pharmaceuticals #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Following the success of Chinook Therapeutics, a Novartis Company, founded by Versant Ventures in 2019 and later acquired by Novartis, the companies have now unveiled Borealis Biosciences, Inc.. With $150 million in funding, #Borealis has been launched to develop #RNATherapeutics for #KidneyDiseases. This new venture represents another significant #Collaboration between #Novartis and #VersantVentures. #BorealisBiosciences has been established to address major #UnmetNeeds in #KidneyDiseaseTreatment through #NextGeneration #RNAMedicines. This builds on the successful journey of #ChinookTherapeutics, which was acquired by Novartis in 2023 for up to $3.5 billion, including late-stage assets for #ImmunoglobulinANephropathy (IgAN). Novartis has committed up to $100 million upfront, with additional near-term research funding, and holds an option to #Acquire two programs from Borealis for up to $750 million. This collaboration underscores Novartis' unwavering commitment to advancing #RenalScience and exploring new frontiers in #Biotechnology. Stay tuned for more updates as Borealis Biosciences works towards transforming kidney disease treatment! #Biotech #RNAtherapeutics #KidneyDisease #Novartis #VersantVentures #BorealisBiosciences #HealthcareInnovation #Pharmaceuticals #MedicalResearch Detailed News: https://lnkd.in/dh2Jvpzn Follow our page for more industry updates: https://lnkd.in/de5zNWmK

RedHill Biopharma Ltd. has successfully launched #Talicia, a #Novel #TripleTherapyCombination, in the #UnitedArabEmirates. Talicia, consisting of #OmeprazoleMagnesium, #Amoxicillin, and #Rrifabutin. It is designed to eradicate #HelicobacterPylori (H. pylori) infections, a major risk factor for #GastricCancer. With its unique formulation and enhanced #Efficacy, Talicia offers a significant advancement in the #Treatment of H. pylori infections, particularly in patients with #Resistance to #TraditionalTherapies or underlying conditions such as #Obesity or #Diabetes. By addressing the growing burden of H. pylori infections, Talicia has the potential to improve #PatientOutcomes and reduce the #Incidence of related complications. #RedHillBiopharma #Talicia #Hpylori #Gastroenterology #UAE #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification Detailed News: https://lnkd.in/d5jieHNT Follow our page for more industry updates: https://lnkd.in/de5zNWmK

In Season 2, Episode 12 of our Pipeline Analysis series, we explore Novo Nordisk’s significant advancements. Here are some of the key highlights 💼 Financial Strength: Net Revenue H1 2024: DKK 133.4 billion R&D Investment Q2 2024: DKK 16.1 billion 🧪 Pipeline Advancements: Awiqli® recieved approval in the EU, Japan, and China; a Complete Response Letter (CRL) received for insulin icodec in the US; and the label extension for Wegovy® in the EU based on the SELECT cardiovascular outcomes trial (CVOT). 🏆The GLP-1 class continues its global expansion, driving a 25% increase in Diabetes care sales, fueled by strong performances from Rybelsus®, Ozempic®, and Victoza®. Stay connected for more in-depth insights and updates from RAS LifeScience Solutions! #PipelineAnalysis #BiopharmaUpdates #PharmaInsights #DrugAdvancements #HealthcareInnovation

#ShanghaiHenliusBiotech announced that its partner, Accord Healthcare Inc. (a subsidiary of Intas Pharmaceuticals), has obtained #MarketingApproval (Notice of Compliance) from Health Canada | Santé Canada for #HLX02, a #Trastuzumab #Biosimilar. This biosimilar, known as #HANQUYOU in #China, #HERCESSI in the #US, and #Zercepac in #Europe, has been approved in #Canada under the brand name #Adheroza for the treatment of #EarlyBreastCancer, #MetastaticBreastCancer, and #MetastaticGastricCancer. #HLX02 is a #MonoclonalAntibody (mAb) biosimilar developed in China. It has previously been approved in China, the #EuropeanUnion (EU), and the #UnitedStates (U.S.), following #MarketingAuthorizations from the #EuropeanCommission (EC), #NationalMedicalProductsAdministration (NMPA), and FDA in July and August 2020, and April 2024, respectively. So far, HLX02 has gained approval in 48 countries and regions, including China, the U.S., the #UnitedKingdom, #France, #Germany, #Switzerland, #Australia, #Finland, #Spain, #Brazil, #Argentina, #SaudiArabia, and #Thailand, covering #Asia, #Europe, #LatinAmerica, #NorthAmerica, and #Oceania. The #HealthCanada approval of HLX02 was supported by a comprehensive set of analytical, non-clinical, and #ClinicalStudyData submitted by Henlius. The company conducted extensive head-to-head studies for HLX02, including comparative quality analytical studies, a phase 1 #Pharmacokinetic (PK) similarity study, and a #GlobalMulticenter #PhaseIII #ClinicalStudy. These studies demonstrated that HLX02 is highly #Comparable to the #ReferenceProduct #Trastuzumab in terms of #Quality, #Safety, and #Efficacy. For detailed news: https://lnkd.in/dsMN97uD Follow our page for more industry updates: https://lnkd.in/de5zNWmK #Henlius #Trastuzumab #Biosimilar #AccordHealthcare #HealthCanada #BreastCancer #MetastaticCancer #Oncology #PharmaNews #GlobalHealth #Biotech #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization

AbbVie and Genmab secured European Commission #Approval for their #BispecificAntibody #Tepkinly (epcoritamab) for the treatment of relapsed or refractory #FollicularLymphoma, the most common type of low-grade non-Hodgkin lymphoma. This milestone followed Tepkinly’s FDA approval for the same indication two months prior. The European Commission granted #ConditionalApproval, allowing Tepkinly to be used as a #Monotherapy in adult patients who had undergone at least two prior lines of therapy. This #Authorization was made valid for one year and could be renewed annually, contingent on #AbbVie and #Genmab providing additional data to confirm that the therapy's benefits outweighed its risks. Tepkinly was designed as a subcutaneous bispecific antibody targeting both the #CD3Receptor on #TCells and the #CD20 protein on #BCells, which activated T cells to destroy malignant B cells. The expansion into follicular lymphoma marked a significant step forward in establishing #Tepkinly as a core therapy across multiple B-cell malignancies. AbbVie’s Vice President and Therapeutic Area Head for Hematology, Mariana C., emphasized the importance of this approval, highlighting Tepkinly’s growing utility in #HematologicalCancer treatment. Tepkinly was initially developed by Genmab, which partnered with AbbVie in 2020 in a deal worth up to $4.25 billion. The therapy first gained #EuropeanApproval in February 2022 for diffuse large B-cell lymphoma (DLBCL), and with this latest approval, it became the first and only EC-approved subcutaneous #BispecificTCellEngager indicated for both #Relapsed or #RefractoryFollicularLymphoma and #DLBCL. The EC’s decision was based on data from the EPCORE NHL-1 study, which showed an #OverallResponseRate of 83% and a #CompleteResponseRate of 63%. The median duration of response was 21.4 months. Tepkinly’s #Safety profile was found to be consistent with previous studies, with common #SideEffects including injection site reactions, fatigue, and neutropenia. #AbbVie #Genmab #Tepkinly #Epcoritamab #Hematology #Oncology #CancerTreatment #FDAApproval #EuropeanCommission #EMA #FDA #BispecificAntibody #NonHodgkinLymphoma #PharmaNews #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization  Detailed News: https://lnkd.in/dKd8GAhu Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Season 2, Episode 11 of our Pipeline Analysis series delves into Eli Lilly’s notable advancements. Here are some of the key takeaways 💼 Financial Strength: Net Revenue H1 2024: $20 billion R&D Investment Q2 2024: $2.7 billion Lilly's Q2 investment growth is primarily fueled by recent and upcoming product launches, rapid pipeline development, and significant progress in their ambitious manufacturing expansion plans. 🧪 Pipeline Advancements: Lilly's Kisunla™ has been approved in the U.S. for the treatment of adults with Alzheimer’s disease. Additionally, tirzepatide has been submitted for regulatory approval in both the U.S. and EU for the treatment of moderate-to-severe obstructive sleep apnea and obesity. 🏆Lilly's revenue increased by 36%, propelled by strong performances from Mounjaro®, Zepbound®, and Verzenio®. Stay tuned for more profound insights and updates from RAS LifeScience Solutions! #PipelineAnalysis #BiopharmaUpdates #PharmaInsights #DrugAdvancements #HealthcareInnovation

#Didyouknow that 1 in 10 people are living with #diabetes, globally. The worldwide prevalence of diabetes is approximately 537 million as of 2021, which is expected to rise to 643 million by 2030. Rising levels of #obesity, #sedentarylifestyle and poor diet are the primary drivers of increasing prevalence. #Type2diabetes is the most common type of diabetes, accounting for around ~90% of all cases. Some of the common symptoms of diabetes include frequent urination, increased thirst, fatigue etc. There are multiple pharmacotherapeutic options available for #treatment of T2D such as sulphonylureas, #DPP-4inhibitors, #GLP1receptoragonists and #SGLT2inhibitors. In addition to pharmacotherapy, T2D management also includes maintaining a healthy diet, increased physical activity, smoking cessation and maintaining a healthy body weight. Type 2 diabetes increases the risk of other related cardio-renal-metabolic conditions such as #obesity, #heartfailure and #chronickidneydisease. Given the interconnectedness of these #CRM indications and the high prevalence of obesity in people with diabetes, the recent EASD/ADA 2023 guidelines for the management of diabetes highlights ‘weight management’ as an equally important treatment goal Let’s spread awareness and encourage proactive health monitoring and healthy lifestyle. Watch our video to learn more and stay tuned for upcoming episodes in this series!    Follow our page for such related content: https://lnkd.in/de5zNWmK  #Type2diabetes #T2D #Diabetes #Awareness #Health #Wellness #EarlyDetection #Healthcare #HealthScreening #Obesity #RASLSS #cardiomrenaletabolic #CVRM